Mazur Bogdan, Szczepański Tomasz, Karpe Jacek, Sońta-Jakimczyk Danuta, Bubała Halina, Torbus Magdalena
Department of Pediatric Hematology and Oncology, Silesian Medical Academy, Ul. 3 Maja 13/15, 41-800 Zabrze, Poland.
Leuk Res. 2006 Jan;30(1):33-6. doi: 10.1016/j.leukres.2005.05.024. Epub 2005 Jul 21.
Treatment-related immunosuppression in patients with acute lymphoblastic leukemia (ALL) is associated with increased susceptibility to infectious diseases, also after the treatment. The aim of the present study was the detailed evaluation of T lymphocyte subsets in peripheral blood in children after treatment of ALL. All children were treated according to the BFM 90 protocol. The patients were divided into 5 groups of 30 children in each, depending on the time from cessation of the ALL treatment. A control group consisted of 30 healthy children subjected to elective "1-day" surgery. The children's age ranged from 6 to 18 years. The examinations were performed in FACScan flow cytometer with the use of wide set of monoclonal antibodies: CD3, CD4, CD8, TCRalphabeta, TCRgammadelta, CD19, CD25, CD45RA, CD45RO, CD69, HLA-DR, CD16 and CD56, which particularly allowed detailed analysis of T lymphocytes. The results showed that most parameters in children 1 year after ALL treatment completion were similar to healthy children. However, we observed persistently low CD4+ T cell numbers, both CD45RA+ as well as CD45RO+ subsets as compared to the control group. This might reflect decreased regenerative potential of immunological system in children 1 year after ALL treatment.
急性淋巴细胞白血病（ALL）患者治疗相关的免疫抑制与治疗后对传染病易感性增加有关。本研究的目的是详细评估ALL治疗后儿童外周血中的T淋巴细胞亚群。所有儿童均按照BFM 90方案进行治疗。根据ALL治疗停止后的时间，将患者分为5组，每组30名儿童。对照组由30名接受择期“一日”手术的健康儿童组成。儿童年龄在6至18岁之间。使用多种单克隆抗体在FACScan流式细胞仪上进行检测：CD3、CD4、CD8、TCRαβ、TCRγδ、CD19、CD25、CD45RA、CD45RO、CD69、HLA-DR、CD16和CD56，这些抗体特别有助于对T淋巴细胞进行详细分析。结果显示，ALL治疗完成后1年的儿童中，大多数参数与健康儿童相似。然而，与对照组相比，我们观察到CD4 + T细胞数量持续偏低，包括CD45RA +以及CD45RO +亚群。这可能反映了ALL治疗后1年儿童免疫系统再生潜力的下降。
